FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Monday

 

MS Drug Costs: The Elephant in the Examination Room


























A lot of factors go into our decisions when we select the drug we’re going to use to fight our MS.

How well will it work? What are the possible side effects and how serious could they be? How will using the drug (taking a pill, giving myself a shot, getting an infusion), affect my lifestyle? And, more than I think some people realize, what will the drug cost me?


I wonder if cost is, too often, an overlooked factor when we discuss our MS therapy options with our doctors. We don’t want to admit that a treatment that might help us might not be affordable while the doc’s primary concern is prescribing the treatment that’s best for us. (I regularly read allegations from patients that their doctors are prescribing drugs because the drug companies are providing kick-backs to those doctors, but that’s a subject for another column). Cost is the elephant in the room — hard to ignore, but not easy to deal with.

Looking at drugs from a cost-effective viewpoint

A recent study by the Institute for Clinical and Economic Review, reviewing the cost-effectiveness of 16 disease-modifying therapies, recognizes this problem:

A diagnosis of MS poses many burdens, including economic hardships that are underappreciated in most economic analyses of MS. These include lost wages from missed work, the need to transition from full- to part-time work, the inability to continue working, and the high cost of medications and medical equipment.”

Patients want their provider to be able to choose the medication that is best for them without restriction, but feel that their choice of therapy is driven by insurance coverage and the willingness of their provider to appeal coverage denials. The high cost of DMTs for MS can result in large out-of-pocket costs for individuals who are unaware of, or ineligible for, patient-assistance programs offered by manufacturers or non-profit organizations.”

Of the 16 disease-modifying therapies reviewed, the study singles out one, Lemtrada (alemtuzumab), as the most cost-effective, comparing its lifetime costs with the number of expected exacerbations, quality of life and life expectancy. But, cautions the report, Lemtrada comes with a safety cost.

The costs of alemtuzumab were much lower than other DMTs, as it does not require continuous dosing over time and the manufacturer covers the costs of laboratory monitoring, which led to lower incremental cost-effectiveness ratios. Caution in considering the cost-effectiveness findings for alemtuzumab is required, however, given the safety concerns relevant to this DMT.”

Don’t discount other drugs

When you weigh all of the variables, you may find that another DMT is better for your personal needs. The ICER study is full of charts comparing the clinical benefits, risks, quality of life and yearly costs of the various DMTs. The report is complicated, filled with statistical analysis, but it’s worth at least a scan before your next visit to the neurologist. You’ll be better prepared to discuss the elephant in the treatment room.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News